CD37 and non-Hodgkin lymphoma: CD37-directed radioimmunotherapy (RIT) with the fully murine antibody lutetium-177 (177Lu; T1/2: 6.65 d)-lilotomab satetraxetan, was recently evaluated in a phase 1/2a study in relapsed/refractory indolent NHL patients and showed encouraging results1–3.